ReviewInternational journal of retina and vitreous2018
The diagnosis and treatment of primary vitreoretinal lymphoma: a review.
Review in International journal of retina and vitreous, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Exploration of the Optimal Treatment Modality for Vitreoretinal Lymphoma: A PRISMA Compliant Meta-Analysis and Systematic Review.Cancer medicine · 2025Pooled it
- Article
- Efficacy and Safety of Response-Adapted Intravitreal Methotrexate Therapy for Vitreoretinal Lymphoma: A Two-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Review
- Spectrally Resolved (Colour-Coded) Fundus Autofluorescence Using the EIDON System in Vitreoretinal Lymphoma.Ophthalmology and therapy · 2026Article
- Successful use of intravitreal rituximab as salvage therapy for relapsed vitreoretinal lymphoma.Indian journal of ophthalmology · 2026Observational
- Advanced Multimodal Imaging in Granulomatous Uveitis: From Differential Diagnosis to Treatment Monitoring and Surgical Integration.Journal of clinical medicine · 2026Review
- White spots to spot vitreoretinal lymphoma.Eye (London, England) · 2026Article
- Cytologic Diagnosis of Large B-Cell Lymphoma: Diagnostic Approach and Differential Diagnosis.Acta cytologica · 2026Review
- Real world outcomes of intravitreal and systemic therapy in primary and secondary vitreoretinal lymphoma.Scientific reports · 2026Article
- Recent advances in the diagnosis and treatment of refractory ocular inflammatory diseases: focus on uveitic macular edema, acute retinal necrosis, and vitreoretinal lymphoma.Japanese journal of ophthalmology · 2026Review
- A noninvasive machine learning model using a complete blood count for screening of primary vitreoretinal lymphoma.Nature communications · 2025Article
- Aqueous humor biomarkers in ocular oncology: Insights and advances.Cell reports. Medicine · 2025Review
- Molecular analysis of bilateral T-cell vitreoretinal lymphoma.NPJ precision oncology · 2025Article
- Primary vitreoretinal lymphoma: diagnosis, treatment, and prognosis-a review of current knowledge and future directions.Blood science (Baltimore, Md.) · 2025Review
- A glaucoma drainage implant functioning as a sanctuary site for vitreoretinal lymphoma.American journal of ophthalmology case reports · 2025Article
- Clinical guidelines for the diagnosis and treatment of vitreoretinal lymphoma in Chinese patients (2024).Eye and vision (London, England) · 2025Review
- Intraocular Lymphoma: A Review.Journal of ophthalmic & vision research · 2025Review
- FACTORS ASSOCIATED WITH DELAYED DIAGNOSIS IN PATIENTS WITH PRIMARY VITREORETINAL LYMPHOMA.Retina (Philadelphia, Pa.) · 2024Article
- Diagnosis of primary vitreoretinal lymphoma masquerading infectious retinitis by retinal biopsy.Journal of ophthalmic inflammation and infection · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To describe the recent diagnostic and treatment options for the most predominant form of primary vitreoretinal lymphoma (PVRL), namely diffuse large B cell lymphoma. This is mainly based on the experience at the Mayo Clinic as well as a partial review of the literature. MYD88 L265P mutation is seen in about 80% of cases; therefore, a polymerase chain reaction for this mutation helps in making the diagnosis that has been notoriously difficult to make. Local therapy using intravitreal methotrexate and rituximab has been very helpful in the treatment of the local disease. Systemic high-dose intravenous methotrexate is helpful in treating bilateral disease in conjunction with intravitreal therapy. Whether it is helpful in preventing or delaying the development of central nervous system lymphoma (CNSL) is still in dispute. If there is development of CNSL or recurrent ocular disease, alternatives to high-dose methotrexate under investigation include pomalidomide, stem cell transplantation, or ibrutinib, with or without local therapy. Vitrectomy alone might be helpful as a debulking procedure. Because of the risks of redevelopment of disease, local radiation should be given if other options are not possible. Aqueous levels of IL10 are helpful in following the redevelopment of local disease. Conclusion: Although PVRL is still a difficult disease to diagnose and treat, new advances are helping to make these easier. Larger collaborative studies will be helpful in determining better treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.